Elacestrant for estrogen receptor-positive uterine sarcoma
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether elacestrant, a drug that blocks estrogen, can help people with certain types of uterine sarcoma that have strong estrogen receptors. It may slow or stop cancer growth in tumors that rely on estrogen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of uterine sarcoma (leiomyosarcoma, endometrial stromal sarcoma, adenosarcoma, or PEComa) that has spread or cannot be surgically removed.
- Your tumor must have strong estrogen receptor (ER) levels (at least 75% of cells) based on a previous biopsy.
- You need to be 18 or older, able to swallow pills, and willing to follow the study schedule.
- You must have adequate organ function (kidney, liver, blood counts) as shown by recent blood tests.
- If you are a woman who can become pregnant, you must agree to use effective non-hormonal birth control during and for 6 months after treatment.
- You should not have other active cancers or unstable medical conditions that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
This trial tests a new hormone therapy pill, elacestrant, for people with a specific type of breast cancer (ER+, HER2-) that has a certain genetic change (ESR1 mutation) and has grown despite previous hormone therapy. The goal is to see if this drug can help control the cancer.
This trial tests elacestrant, a new hormone therapy drug, in women whose advanced or spread breast cancer has stopped responding to first-line hormone treatment. The drug is designed to work against a specific genetic change (ESR1 mutation) that can develop in these cancers.
This trial tests an oral drug called elacestrant in women whose ER+/HER2- breast cancer has worsened after at least one hormone therapy. It is for those with a specific genetic change (ESR1 mutation) and advanced or metastatic disease.
This trial tests a new hormone therapy (elacestrant) alone or combined with a targeted pill (abemaciclib) for people with advanced or recurrent endometrial cancer that is hormone-receptor-positive. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
Hear when a new Uterine Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.